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Background: Gingival crevicular fluid (GCF) biomarkers associated with bone resorption may be useful
to determine periodontal disease status and response to therapy. The pyridinoline cross-linked carboxy-ter-
minal telopeptide of type I collagen (ICTP), a bone-specific degradation product, and interleukin 1-beta (IL-
1), a potent bone-resorptive cytokine, have both been associated with periodontal disease activity. Minocy-
cline is a tetracycline derivative possessing antimicrobial effects on periodontal pathogens and inhibitory
properties on matrix metalloproteinases (MMPs) associated with tissue destruction. The aim of this study
was to evaluate the effect of periodontal treatment in the form of scaling and root planing (SRP) and locally
administered minocycline microspheres on the GCF levels of ICTP and IL-1.
Methods: Forty-eight chronic periodontitis patients were randomly assigned to 2 groups (SRP plus sub-
gingival application of vehicle control [SRP + V], or SRP plus subgingival application of minocycline micro-
spheres [SRP + M]) and monitored at 8 sites per subject at baseline and 1, 3, and 6 months. Four shallow
(PD ≤3 mm) and 4 deep (PD ≥5 mm) sites were evaluated for both marker levels and for probing depth
(PD), clinical attachment level (CAL), and bleeding on probing (BOP). Eight periodontally healthy control
subjects with no probing depths >3 mm and no loss of attachment were also monitored at the same time
intervals. GCF levels of ICTP and IL-1 were determined using radioimmunoassay and enzyme-linked
immunosorbent assay techniques, respectively.
Results: Significant differences (P <0.001) in GCF levels of ICTP and IL-1 were found between deep and
shallow sites at all time points in both treatment groups. In addition, healthy subjects demonstrated signif-
icantly reduced levels of both markers compared to both shallow and deep sites in periodontitis patients
(P <0.001). Only the SRP + M treated patients exhibited significant reductions (P <0.05) in both ICTP and
IL-1 levels 1 month after treatment. Furthermore, the SRP + M group demonstrated significantly lower IL-1
levels (P <0.02) at 1 month compared to the SRP + V group.
Conclusions: Results of this study indicate that GCF levels of ICTP and IL-1 correlate with clinical mea-
sures of periodontal disease and may aid in assessing disease status and response to periodontal therapy.
Furthermore, local administration of minocycline microspheres led to a potent short-term reduction in GCF
IL-1 levels. Additional studies are needed to address whether repeated administration of scaling and root
planing along with minocycline microspheres will achieve long-term reductions in GCF ICTP and IL-1 lev-
els. J Periodontol 2002;73:835-842.
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Periodontal diagnostic methods have traditionallyrelied on visual and physical assessments of gin-gival inflammation and periodontal tissue damage
(e.g., gingival redness, bleeding on probing, probing
depth and clinical attachment level measurements,
and radiographic examination).1 These methods have
proven effective as post hoc indicators of periodontal
disease history; however, they are unable to identify
highly susceptible patients or to distinguish between
disease-active and inactive sites.2-4 Therefore, diag-
nostic tests that can detect the presence of active dis-
ease, predict future disease progression, and evaluate
the response to periodontal therapy may prove valu-
able in improving the clinical management of peri-
odontal patients.5-7
Gingival crevicular fluid (GCF) is a modified serum
transudate or inflammatory exudate derived from the
periodontal tissues that appears during altered states
of vascular permeability associated with gingival
inflammation.3,8 GCF constituents are derived from
serum, host connective tissue and epithelium, inflam-
matory cells, and bacteria.8 Many GCF components
have been evaluated for potential use as periodontal
diagnostic aids.3,8 However, most of the investigated
markers are not specific for alveolar bone destruction,
and may therefore not distinguish between gingivitis
and active periodontitis (i.e., progressive attachment
or alveolar bone loss).9
Pyridinoline cross-links represent a class of collagen
degradative molecules that include pyridinoline, deoxy-
pyridinoline, N-telopeptides, and C-telopeptides.10,11
Subsequent to osteoclastic bone resorption and colla-
gen matrix degradation, pyridinoline, deoxypyridinoline,
and amino- and carboxy-terminal cross-linked telopep-
tides of type I collagen (ICTP) are released into the
circulation. Because the cross-links and cross-linked
telopeptides result from post-translational modifica-
tion of collagen molecules, they cannot be recycled
during collagen synthesis, and are therefore consid-
ered specific for bone resorption.12 Elevated serum
ICTP and other pyridinoline cross-link levels have been
shown to correlate with the bone-resorptive rate in sev-
eral osseous metabolic diseases, including osteoporo-
sis, rheumatoid arthritis, and Paget’s disease.13-15
Serum ICTP levels have also been used as prognostic
indicators in several primary and metastatic bone
tumors such as multiple myeloma and prostate can-
cer.16,17
Several investigations have recently explored the
ability of pyridinoline cross-links to detect bone resorp-
tion in periodontitis18-22 and peri-implantitis.23 Addi-
tionally, treatment with a matrix metalloproteinase
(MMP) inhibitor significantly reduced GCF ICTP levels
coincident with suppression of MMP-8 and MMP-13 in
periodontitis patients.20 The results of these studies
suggest that utilization of ICTP may be beneficial to
identify and predict periodontal disease progression
and monitor response to treatment.
Interleukin-1 (IL-1) is a potent bone-resorbing
cytokine produced by a variety of cells including mono-
cytes, neutrophils, fibroblasts, and keratinocytes.1,24
IL-1β is the major form secreted by monocytes, and
its production is stimulated by bacterial lipopolysac-
charide.25 Once secreted, IL-1 may activate lympho-
cytes, incite macrophage chemotaxis and prostaglandin
production, and stimulate osteoclastic resorption of
bone.26 IL-1 has been detected in gingival biopsies and
in the GCF of periodontal patients.27-31 Cross-sectional
studies have also shown increased GCF IL-1 levels in
sites with periodontitis compared to healthy sites,30
and at sites with experimental gingivitis.32
Minocycline HCl is a tetracycline derivative that is
active against a broad spectrum of Gram-negative and
Gram-positive anaerobes including organisms impli-
cated in chronic periodontitis.33 In addition, tetracy-
cline derivatives such as minocycline inhibit MMPs
that destroy constituents of the periodontium includ-
ing collagen, elastic fibers, proteoglycans, and fibro-
nectin.34-36 Recently, minocycline has been incorpo-
rated into a controlled-release bioabsorbable polymer
(poly glycolide-co-dl-lactide) or PGLA, which serves
as the encapsulating medium. This delivery system
releases the antibiotic over a 2-week period at the site
of administration at concentrations exceeding 300
µg/ml as measured in the GCF.37 A recent clinical trial
demonstrated that utilization of this therapy§ signifi-
cantly enhanced scaling and root planing (SRP) when
compared to SRP alone.38
The aim of this investigation was to examine the
effect of SRP and locally delivered minocycline micro-




Forty-eight patients with moderate to severe chronic
periodontitis participated in this clinical trial. These
patients were required to have at least 4 teeth with prob-
ing depth measurements of 6 to 9 mm that bled upon
probing. Eligible subjects had not received any peri-
odontal therapy for a minimum of 6 months and no
antibiotic treatment for at least 3 months prior to the
study, and were not chronically treated (i.e., 2 weeks or
more) with any medication known to affect periodontal
status (e.g., phenytoin, calcium antagonists, cy-
closporin, coumadin, and non-steroidal anti-inflamma-
tory drugs). In addition, 8 periodontally healthy control
subjects exhibiting no attachment loss and no ra-
diographic bone loss were also recruited. The study pro-
tocol was approved by the Institutional Review Boards
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at both the University of Michigan and Stony
Brook University, and informed consent was
obtained in writing from each subject prior
to study commencement. This was a ran-
domized, single-masked, vehicle-controlled
6-month study with 2 parallel arms. The
study presented is a substudy of a multi-
center investigation recently reported by
Williams et al.38 In addition, results derived
from an additional arm (SRP alone) have
recently been published.18 The 2 arms of the
present study were: 1) SRP plus subgingival
application of minocycline microspheres
(SRP + M), and 2) SRP plus subgingival
application of vehicle (SRP + V).
Collection of GCF was performed at
baseline (prior to treatment), and at 1, 3, and 6
months. After the baseline procedures (i.e., GCF sam-
pling and clinical measurements) were completed,
SRP was performed using hand and ultrasonic instru-
mentation. A maximum of 2 sessions within 14 days
with no time limitation was allowed to complete each
subject. Local anesthetic was used at the discretion of
the clinician. After SRP was completed, patients were
stratified according to smoking status and randomly
assigned to treatment groups. Smoking status was
defined as positive or negative based upon whether the
patient had used tobacco products within the last 6
months. Study treatments (minocycline microspheres
or vehicle) were subgingivally applied at baseline to
all sites with PD ≥5 mm. Sites in the SRP + M group
were given a unit dose of 4 mg containing 1 mg of
minocycline and 3 mg of polymer, while sites in the
SRP + V group received 3 mg of polymer only. Study
treatments were reapplied at 3 and 6 months at all
sites initially treated at baseline. The subjects in the
periodontally healthy control group received a pro-
phylaxis at baseline and no other treatment through-
out the trial. An outline of the study design is sum-
marized in Table 1.
GCF Sampling
For the periodontitis patients, each subject was mon-
itored at 8 sites at baseline (prior to SRP), and 1, 3,
and 6 months after treatment. Four shallow (PD ≤3
mm at screening, no radiographic alveolar bone loss)
and 4 deep (PD ≥5 mm at screening, ≥3 mm from
cemento-enamel junction to bone crest) sites were
monitored longitudinally in each subject for both
marker levels (i.e., ICTP and IL-1). Only deep sites
received subgingival application of minocycline micro-
spheres or vehicle. ICTP and IL-1 levels were deter-
mined at different sites within each subject (i.e., 2 shal-
low/2 deep sites per mediator for a total of 8 sites per
subject). For the periodontally healthy control sub-
jects, GCF samples were collected from 4 randomly
selected sites (no attachment loss, PD ≤3 mm) at base-
line and 1, 3, and 6 months. The area around each site
sampled was dried and supragingival plaque removed.
GCF was collected for 30 seconds using methylcellu-
lose strips. Each strip was placed gently into the gin-
gival crevice until slight resistance was felt, and GCF
volume was determined.¶ Following collection and vol-
ume determination, the samples were kept on ice for
transport to the laboratory and stored at −20°C.
ICTP. The laboratory procedures for analysis of
ICTP samples were performed as described by Gian-
nobile et al.19 The frozen samples were brought to
room temperature, followed by elution of proteins by
microcentrifugation. Levels of ICTP were determined
using a radioimmunoassay technique# as previously
described.39
IL-1. The IL-1 content was determined by using a
commercially available enzyme-linked immunosorbent
(ELISA) assay** based on a double antibody sandwich
technique described by Payne et al.40 Both ICTP and
IL-1 were reported as total amounts per time of col-
lection (pg/30-second sample). All analyses were per-
formed with masking of the treatment groups main-
tained.
Clinical Measurements
Clinical measurements were completed at a total of
384 sites (i.e., 48 subjects × 8 sites/subject) at base-
line and 1, 3, and 6 months. Examiners were masked
in regards to the treatment that each subject received.
The parameters recorded included: 1) probing depth
(PD), measured from the gingival margin to the api-
cal penetration of the probe tip in millimeters; 2) clin-
ical attachment level (CAL), measured from either the
cemento-enamel junction or restoration margin to the
apical penetration of the probe tip in millimeters; and
3) bleeding on probing (BOP), recorded dichotomously
837
   Periopaper, IDE-Interstate, Amityville, NY.
¶ Periotron 6000, Harco Electronics, Tustin, CA.
#   DiaSorin Inc., Stillwater, MN.
** Cayman Chemical Company, Ann Arbor, MI.
Table 1.
Study Outline
Screening Baseline 1 Month 3 Months 6 Months
Informed consent/medical 
and periodontal history X
GCF samples X X X X
Clinical parameters X X X X
Scaling and root 
planing X
Treatment application X X X
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as 0 or 1. All clinical measure-
ments were performed after GCF
sampling using a manual probe.††
Five examiners (from 2 test cen-
ters) performed all clinical mea-
surements and were calibrated
prior to the study to ensure ade-
quate intra- and interexaminer
reliability. Interexaminer reliabil-
ity was determined using the intra-
class correlation coefficient41 to
compare an experienced examiner
designated as the gold standard
to the 5 examiners participating in
this study. The intraclass correla-
tion coefficients for probing depth
and attachment level measure-
ments ranged from 0.90 to 0.97,
and 0.85 to 0.94, respectively.
Intra-examiner reliability was
determined utilizing the percent
agreement within 1 mm between
2 passes and a weighted kappa
statistic. The percent agreement
within 1 mm ranged from 95.5% to 97.3% and 90.0%
to 95.1% for probing depth and attachment level mea-
surements, respectively. The weighted kappa statistic
ranged from 0.92 to 0.97 and 0.88 to 0.92 for prob-
ing depth and attachment level measurements, respec-
tively.
Statistical Analysis
Mean values for biochemical mediators (ICTP and IL-1)
were calculated for each site at all time points (baseline,
1, 3, and 6 months)
and averaged within a
subject and then across
subjects in the 2 groups.
Marker levels at each
time interval were com-
pacted and analyzed at














meters (PD, CAL, and
BOP) were compared to ICTP and IL-1 levels utilizing
correlation coefficients, which were analyzed for sig-
nificance using Fisher’s r to z test.
RESULTS
Subject Characteristics
Characteristics of the study subjects at baseline are
presented in Table 2. Overall, no significant differences
838
†† PCP-UNC 15, Hu-Friedy Manufacturing Co., Chicago, IL.
Table 2.
Subject Group Characteristics at Baseline*
Healthy Subjects SRP Plus Vehicle SRP Plus Minocycline 
(n = 8) (n = 25) (n = 23)
Age in years 28.7 45.1 46.7
(range) 26.2 – 34.3 30.9 – 64.9 34.9 – 70.4
% Female 25 60 69
% Smokers 37.5 52.1 52.1
% Bleeding on probing 12.5 72.5 77.2
Probing depth (mean ± SE)
All sites 2.10 ± 0.11 4.28 ± 0.16 4.42 ± 0.18
Shallow sites N/A 3.00 ± 0.11 3.04 ± 0.10
Deep sites N/A 5.57 ± 0.14 5.79 ± 0.19
Attachment level (mean ± SE)
All sites 1.40 ± 0.12 4.39 ± 0.18 4.42 ± 0.20
Shallow sites N/A 3.17 ± 0.14 3.13 ± 0.11
Deep sites N/A 5.61 ± 0.21 5.71 ± 0.28
* No significant differences were noted in demographic or clinical parameters between the vehicle and
minocycline treatment groups.
Table 3.
ICTP and IL-1 Levels in Deep and Shallow Sites in
Periodontal Patients and Healthy Sites in Control Subjects
(pg/site  SE)
Healthy Subjects* SRP Plus Vehicle 
(n = 8) (n = 25)
ICTP IL-1
ICTP IL-1 Shallow Deep Shallow Deep
Baseline 27.88 ± 9.65 1.71 ± 0.76 154.21 ± 18.33 207.82 ± 18.66 36.47 ± 5.45 60.61 ± 9.10
1 month 31.76 ± 12.92 1.68 ± 1.09 130.65 ± 15.49 171.22 ± 20.03 21.01 ± 3.60 66.31 ± 8.36
3 months 32.84 ± 10.01 1.52 ± 0.53 119.78 ± 13.80 172.98 ± 19.29 31.27 ± 4.97 60.34 ± 9.70
6 months 32.69 ± 10.03 1.54 ± 0.69 124.26 ± 15.27 186.86 ± 20.71 32.56 ± 5.27 56.43 ± 9.53
Note: Only deep sites received local therapy.
* Significantly lower levels of both markers were found in healthy sites in control subjects than both shallow and deep sites 
in periodontal patients at all time points (P <0.01).
† Significant reduction from baseline values (P <0.05).
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were noted in demographic or clinical parameters
between the minocycline and vehicle treatment groups
or between sites within these groups sampled for ICTP
and IL-1. Mean ages were 45.1 and 46.7 years for the
vehicle and minocycline group, respectively. The per-
centage of smokers was 52% in each group. All subjects
completed the scheduled examination sessions. A total
of 1,536 samples were therefore available for analysis
(8 sites per subject × 48 subjects × 4 time points), half
of which received local therapy (minocycline micro-
spheres or vehicle). The periodontally healthy control
group included 6 males and 2 females, with a mean
age of 28.7 years. This group was significantly younger
than the chronic periodontitis groups (P <0.05). The
mean baseline PD and CAL measurements ± SE at
sampled sites were 2.1 ± 0.11 mm and 1.4 ± 0.12
mm, respectively. There were 3 smokers in the group.
ICTP and IL-1 Levels at Healthy, Shallow, and Deep
Sites
The GCF levels of ICTP and IL-1 in different site strata
(i.e., healthy sites in control subjects, and shallow and
deep sites in periodontal patients) were compared
(Table 3). The healthy control subjects provided 128
sites for analysis (4 sites/subject × 8 subjects × 4 time
points). A total of 1,536 samples were available for
analysis from the periodontitis patients (768 deep sites
and 768 shallow sites). Deep sites in periodontal
patients contained significantly higher levels of both
ICTP and IL-1 than shallow sites in the same patients
(P <0.01). Furthermore, both deep and shallow site
levels of both markers in periodontal patients were sig-
nificantly higher than healthy site levels in the control
subjects (P <0.01) (Table 3). These differences were
statistically significant at baseline and all subsequent
study time points (i.e. 1, 3, and 6 months), except
for ICTP levels between deep and shallow sites in
periodontal patients at the 1-month time point (P =
0.092).
Effects of Treatment on GCF ICTP Levels
The effects of treatment on the GCF ICTP levels in the
2 study groups are presented in Figure 1. Since only
deep sites (≥5 mm PD at baseline) were treated with
minocycline or vehicle, ICTP levels were stratified by
site category (deep versus shallow). In deep sites, sta-
tistically significant reductions in ICTP levels were seen
only at 1 month in the SRP + M group (P <0.05). ICTP
levels were reduced by 33.2% in the SRP + M group
after 1 month, compared to a 17.2% reduction in the
SRP plus vehicle group (Fig. 1). No significant changes
in ICTP levels were seen at shallow sites in any of the
treatment groups (data not shown).
Effects of Treatment on GCF IL-1 Levels
The effects of treatment on the GCF IL-1 levels in the
2 study groups are presented in Figure 2. In deep sites,
statistically significant reductions in IL-1 levels were
noted only at 1 month in the SRP + M treated sites (P
<0.05). Furthermore, at 1 month post-treatment, the
SRP + M group demonstrated significantly lower IL-1
levels (P <0.02) compared to the SRP + V group. This
finding is due to a 38.0% decrease in IL-1 levels 1
month following treatment with SRP + M compared to
a 9.4% increase among patients treated with SRP + V.
No significant changes in IL-1 levels were observed at




ICTP levels after treatment at periodontal sites receiving local
administration of minocycline microspheres. SRP + M was
administered to deep sites (PD ≥5 mm) in 23 patients, while SRP + V
was administered to deep sites in 25 patients. Note potent reductions
in GCF ICTP levels at 1 month in minocycline-treated subjects (P
<0.05), with minimal effects at 3 and 6 months (NS). *Significant
reduction from baseline levels (P <0.05).
Table 3 (continued).
ICTP and IL-1 Levels in Deep and Shallow
Sites in Periodontal Patients and Healthy
Sites in Control Subjects (pg/site  SE)
SRP Plus Minocycline 
(n = 23)
ICTP IL-1
Shallow Deep Shallow Deep
124.45 ± 16.76 200.44 ± 24.92 39.84 ± 8.94 62.20 ± 8.97
113.23 ± 20.45 132.38 ± 16.22† 18.01 ± 3.21 35.54 ± 5.31†
149.23 ± 20.12 200.21 ± 22.98 35.70 ± 10.95 50.03 ± 9.93
84.29 ± 12.05 172.27 ± 19.19 25.81 ± 7.04 59.79 ± 10.74
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Correlation of ICTP and IL-1 Levels With Clinical
Parameters
Correlations among GCF ICTP and IL-1 levels with
clinical parameters (PD, CAL, and BOP) were exam-
ined. Weak, but statistically significant (P <0.001), cor-
relations were demonstrated between marker levels
and all clinical parameters, ranging between 0.13 and
0.37 (data not shown).
DISCUSSION
Identification of patients or sites with progressive dis-
ease or at risk for future periodontal breakdown
remains elusive. Similarly, limitations in measurement
reliability prevent the accurate assessment of a
patient’s response to therapy. Host factors in GCF asso-
ciated with metabolic events responsible for initiation
and progression of periodontitis may be useful to iden-
tify the current status of a patient and determine indi-
viduals and/or sites highly susceptible to disease pro-
gression.3 The results of this longitudinal study
demonstrate that levels of a bone-specific marker
(ICTP) and a cytokine associated with bone resorp-
tion (IL-1) are higher at sites exhibiting moderate to
severe periodontitis compared to sites with less peri-
odontal involvement in periodontitis patients or peri-
odontally healthy individuals. In addition, non-surgi-
cal periodontal therapy consisting of mechanical
debridement and locally delivered minocycline micro-
spheres provided a statistically significant short-term
reduction in IL-1 GCF levels. Therefore, the data sug-
gest that markers evaluated in this study may be mea-
sures of local tissue destruction and indicators of
response to treatment.
The findings of the present study confirm a previ-
ous report by Palys et al.,21 who demonstrated higher
levels of ICTP at shallow sites in both gingivitis and
periodontitis patients compared to periodontally
healthy subjects. In this report, no significant differ-
ences were observed in age between the groups.21
Thus, it appears that levels of pyridinoline cross-links
are not age dependent. Furthermore, Palys et al. noted
no significant differences in ICTP levels at sites exhibit-
ing different probing depths among a cohort of treated
periodontitis patients.21 The findings of both the pres-
ent study and the Palys et al. report suggest that ICTP
levels may be more related to the patient’s overall
level of periodontal tissue destruction and perhaps
their susceptibility to periodontal diseases than to the
periodontal anatomy (i.e., probing depth) at a specific
site.
Significant reductions were demonstrated 1 month
after treatment in GCF ICTP and IL-1 levels only in
patients who received SRP plus minocycline micro-
spheres. The reduction in ICTP was nearly twice that
achieved by SRP plus vehicle, and the IL-1 reduction
was approximately 4-fold. In addition, at the 1-month
visit, IL-1 levels in patients treated with minocycline
microspheres were significantly lower than in patients
treated with vehicle. A similar trend was observed for
ICTP at 1 month; however, the difference was not sta-
tistically significant. Furthermore, in the SRP plus
minocycline group, CAL gains of ≥2 mm after 1 month
in ICTP sites were associated with a statistically sig-
nificant concomitant decrease in ICTP levels of 148.1
pg (55.9%) from baseline values (P <0.05) (data not
shown). The significant improvement noted in bio-
chemical marker levels in the SRP + M group despite
the lack of clear differences in response of clinical
parameters between the 2 groups suggests that marker
levels may provide greater sensitivity than clinical mea-
surements in measuring response to therapy. It is con-
ceivable that changes were present subclinically at the
metabolic level that could not be detected by tradi-
tional clinical measures. This hypothesis is also sup-
ported by the results of correlation testing in which
the associations between ICTP and IL-1 with clinical
parameters were relatively weak. As stated by Lam-
ster et al., GCF markers may provide different mea-
sures of periodontal disease activity than traditional
clinical parameters.42 In this regard, while improve-
ments in clinical parameters were maintained over the
6-month period, GCF levels of ICTP and IL-1 were sig-
nificantly reduced only at 1 month, but elevated lev-
els returned at 3 and 6 months. The reductions exhib-
ited in ICTP and IL-1 in the minocycline group may be
short term and therefore not present 3 months follow-
840
Figure 2.
IL-1 levels after treatment at periodontal sites receiving local
administration of minocycline microspheres. SRP + M was
administered to deep sites (PD ≥5 mm) in 23 patients, while SRP + V
was administered to deep sites in 25 patients. Note strong reductions
in GCF IL-1 levels at 1 month in minocycline-treated patients ( P
<0.05), with minimal effects at 3 and 6 months (NS).At 1 month, IL-1
levels were significantly lower in the SRP + M group compared to the
SRP + V group ( P <0.02). * Significant reduction from baseline levels
( P <0.05) and difference between SRP + M and SRP + V groups at 1
month ( P <0.02).
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ing administration. However, these results may also
reflect the need for additional treatment as SRP was
provided only at baseline and not at follow-up visits.
Additional studies are needed to address whether
repeated administration of SRP along with minocycline
microspheres is required to achieve long-term reduc-
tions in GCF ICTP and IL-1 levels. Further study is
also needed to determine whether treatment regimens
that reduce these markers are associated with improved
patient outcomes.
The observed short-term reductions in ICTP and IL-
1 levels after treatment with SRP plus minocycline may
be related to both the bacteriostatic effect and MMP
inhibitory activities of minocycline.43 Minocycline HCl
is a tetracycline analog that is active against a broad
spectrum of periodontal pathogens.33 Previous studies
have demonstrated improvements in microbial pa-
rameters with the use of locally delivered minocycline
compared to debridement and placebo alone.44,45 The
elevated minocycline concentration achieved with this
delivery system may enhance its anti-infective action
to penetrate the plaque biofilm compared to systemic
administration. In regards to MMP inhibition, it was
demonstrated that systemic administration of 40 to 80
mg of minocycline daily led to a 45% to 80% reduc-
tion in GCF collagenase activity for at least 2 weeks
after initiating treatment. GCF concentrations of
minocycline after systemic administration were
reported to approximate 10 µg/ml. Considering the
reported sustained release concentrations of ≥340
µg/ml for 2 or more weeks achieved with the delivery
vehicle utilized in this study,37 similar or greater anti-
collagenolytic activities may have been responsible for
the observed reductions in the bone-resorptive mark-
ers evaluated. In addition, the known substantive prop-
erties of tetracyclines on adhering to the root surface
may aid in its extended effects.46
Results from this study indicate that GCF ICTP and
IL-1 levels are able to capture the short-term effects
of treatment with SRP and locally administered minocy-
cline microspheres in chronic periodontitis patients.
Further longitudinal studies in larger patient populations
are indicated to more thoroughly establish the utility
of these markers as adjuncts to evaluate patients with
periodontal diseases.
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